Skip to main content
Clinical Trials/NCT02166528
NCT02166528
Unknown
Not Applicable

The Study of Susceptibility Genes Localization for Female Pelvic Floor Dysfunction

Zhiqing, Liang1 site in 1 country200 target enrollmentNovember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Female Pelvic Floor Dysfunction
Sponsor
Zhiqing, Liang
Enrollment
200
Locations
1
Primary Endpoint
susceptibility genes localization
Last Updated
11 years ago

Overview

Brief Summary

Female pelvic floor dysfunction (FPD) is due to defects in the pelvic support structures, degradation, damage or dysfunction. The main problem of which is pelvic organ prolapse(POP), urinary incontinence(UI) and genital tract injury. Although it does not pose a serious threat to life, but affect the patient's quality of life seriously in the physical, psychological, social behavior and other aspects. With the growing aging population, the incidence rate has gradually increased, and increasing demands for people's quality of life simultaneously, more and more attention was raised to PFD as common chronic diseases.

In recent years, the basic research, epidemiology, prevention, diagnosis and treatment of PFD have made great progress, especially in developing gynecological urology theory and reconstructive pelvic surgery. But overall the basic research of PFD is lagging behind, especially susceptibility gene localization and functional studies did not get enough attention.

Registry
clinicaltrials.gov
Start Date
November 2013
End Date
October 2017
Last Updated
11 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Zhiqing, Liang
Responsible Party
Sponsor Investigator
Principal Investigator

Zhiqing, Liang

Director of Obstetrics and Gynecology

Third Military Medical University

Eligibility Criteria

Inclusion Criteria

  • female aging from 30 to 70-year old;
  • preoperative diagnosis of gynecologic malignancies;
  • have the ability to comply with Research programs;
  • voluntarily participate in the study and signed an informed consent form

Exclusion Criteria

  • patients with severe cardiovascular diseases, kidney, liver and other vital organs diseases, bone marrow disease and mental illness;
  • patients suffering from autoimmune diseases;
  • patients with acute infectious disease or infection early phase of infection;
  • patients with urinary tract infection;
  • patients with infection or erosion of ano-genital skin;
  • for any other reason, the researchers considered unsuitable for inclusion.

Outcomes

Primary Outcomes

susceptibility genes localization

Time Frame: 4 years

Based on high-throughput sequencing platform, we expect to screen out susceptibility genes location in PFD, providing theoretical basis for individualized prevention, intervention and treatment.

Study Sites (1)

Loading locations...

Similar Trials